Anti-diabetic drugs treat diabetes by lowering glucose levels in the blood. One class of anti-diabetic drugs that are used in the management of diabetes is Sulfonylurea. Sulfonylurea derivatives are used in the management of diabetes mellitus type 2. They act by increasing insulin release from the beta cells in the pancreas. Diabetes mellitus type 2 is a disease of insulin resistance by cells. Treatments include agents which increase the amount of insulin secreted by the pancreas, agents which increase the sensitivity of target organs to insulin, and agents which decrease the rate at which glucose is absorbed from the gastrointestinal tract.
LGM Pharma is a US based supplier of the following APIs (Active Pharmaceutical Ingredients) from the Sulfonylurea class of Anti-diabetic drugs, for research and development purposes:
- Acetohexamide – used mainly for people whose diabetes cannot be controlled by diet alone.
- Chlorpropamide – a long-acting sulphonylurea. It has more side effects than other sulphonylureas and its use is no longer recommended.
- Tolbutamide – generally has a short duration of action due to its rapid metabolism, and is therefore safe for use in elderly diabetics.
- Tolazamide – other diabetes medicines are sometimes used in combination with tolazamide if needed.
- Glipizide – is an oral medium-to-long acting anti-diabetic drug.
- Gliclazide – classification has been ambiguous, as literature uses it as both a first-generation and second-generation sulfonylurea.
- Glibenclamide (glyburide) – a major cause of drug induced hypoglycemia. Cholestatic jaundice is noted.
- Gliquidone – in addition to its primary function, it assists on the movement of sugar in the blood into the cells in the body.
- Glimepiride – also is available in combination with other diabetes medications such as Rosiglitazone.
Check out our other Popular Research Chemicals, and find the right products to assist you with your R&D needs.
*Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.